葵花药业“药二代”提前离场，2025财报预告迎上市以来首亏｜中药锈带

Core Viewpoint - The resignation of Guanyi, the general manager of Kewang Pharmaceutical, comes at a critical time as the company faces its first annual loss since its listing in 2014, with a projected net profit loss of 240 million to 380 million yuan for 2025 [2][8]. Group 1: Management Changes - Guanyi has resigned from her position as general manager, effective 16 months before the end of her term in June 2027, while retaining her role as a board member [2][3]. - The management transition is seen as a significant decision for Kewang Pharmaceutical, especially during a period of financial downturn [2][3]. - The new general manager, Zhou Jianzhong, is an experienced figure in the pharmaceutical industry, indicating a shift towards a more professional management team [10][11]. Group 2: Financial Performance - Kewang Pharmaceutical is expected to report a net profit loss of 240 million to 380 million yuan for 2025, marking the first annual loss in its history [8]. - The company experienced a sharp decline in revenue, with a 40.76% drop to 3.377 billion yuan in 2024, and a further deterioration in 2025, with a net profit loss of 33.54 million yuan in the first three quarters [4][5]. - The decline in performance is attributed to several factors, including adjustments in distribution channels, increased fixed costs due to reduced production, and rising marketing expenses [5][9]. Group 3: Market Context - The pharmaceutical industry is currently facing a period of instability, with a shift from a growth phase to a more stable or even declining phase [3][5]. - The competitive landscape in the pediatric medicine sector has intensified, impacting Kewang's market position despite the success of its flagship product, "Little Kewang Dew" [6][9]. - The company's previous marketing strategies, heavily reliant on advertising, are being reevaluated in favor of more refined and digital approaches, reflecting a broader industry trend towards professional marketing and operational efficiency [10][12].